Home > Press > Nanostart AG announces record numbers for the first half of 2010
Abstract:
Transparency report in accordance with §17 Section 2 of the general terms and conditions for open markets
* Best first half of year in company history
* Net asset value increases to nearly EUR 144 million
* Cash influx from BioMicro transaction not yet included
Frankfurt-based nanotechnology company Nanostart AG is reporting the best first-half results since the company was founded for the first six months of 2010. In accordance with commercial code, semi-annual net profit totaled EUR 923,000 (previous year EUR -1.4 million). Earlier in the year, Swiss company and global market leader Roche Diagnostics purchased the main product line of American Nanostart holding BioMicro Systems, Inc. Revenues from this transaction are however not included in semi-annual numbers, as the cash transfer took place after the June 30, 2010 reporting date.
In addition to positive earnings results, Nanostart achieved a net asset value of nearly EUR 144 million as of the reporting date. This is approximately EUR 29 million more than at the same point last year. In the conservative calculation of net asset value, shares of unlisted shareholdings - about 80 percent of the current portfolio - are attributed to acquisition costs in the calculations. Only existing shareholdings in Nanostart AG companies that are listed on the stock exchange are entered at market value.
The company continues to pursue international expansion. Acquisition of additional holdings is anticipated this year, especially in Singapore, where Nanostart is investing as a government partner.
Semi-annual numbers are now archived at the Nanostart website in the Investor Relations area. The 2010 semi-annual report will be available September 27 in the company reports section.
Disclaimer:
This notice constitutes neither an offer to sell nor a solicitation of offers to purchase or subscribe to securities. There will be no public offering of securities of Nanostart AG in conjunction with the existing listing of its shares in the "Entry Standard" segment of the regulated unofficial market (Freiverkehr) on the Frankfurt Stock Exchange. This notice does not constitute a securities prospectus. Neither this notice nor the information contained within is intended for direct or indirect distribution within the United States of America, Canada, Australia or Japan. If there is any inconsistency between the German and the English versions of this document, the German version will prevail.
####
About Nanostart
Nanostart AG is the world’s leading nanotechnology investment company. The Frankfurt-based company provides venture capital financing for nanotechnology companies in various growth phases. It also provides the benefits of its experience and expertise to developers of financial instruments and to investors in the nanotechnology sector. For further information about the company, please visit www.nanostart.de.
For more information, please click here
Contacts:
Media contact:
Nanostart AG
Public Relations
Dr. Hans Joachim Dürr
Goethestrasse 26-28
60313 Frankfurt
Germany
phone: +49 (0)69-21 93 96 111
fax: +49 (0)69-21 93 96 122
Copyright © Nanostart
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Financial Reports
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||